Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases

Frontiers in Cell and Developmental Biology, Journal Year: 2024, Volume and Issue: 12

Published: July 16, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty (NAFLD), is the most common disorder worldwide, with an estimated global prevalence of more than 31%. steatohepatitis (MASH), formerly (NASH), a progressive form MASLD characterized by hepatic steatosis, inflammation, and fibrosis. This review aims to provide comprehensive analysis extrahepatic manifestations MASH, focusing on chronic diseases related cardiovascular, muscular, renal systems. A systematic published studies literature was conducted summarize findings systemic impacts MASH. The focused association MASH metabolic comorbidities, cardiovascular mortality, sarcopenia, kidney disease. Mechanistic insights into concept lipotoxic inflammatory "spill over" from MASH-affected were also explored. are highly associated (50%-80%) other comorbidities such impaired insulin response, type 2 diabetes, dyslipidemia, hypertriglyceridemia, hypertension. Furthermore, 90% obese patients diabetes have Data suggest that in middle-aged individuals (especially those aged 45-54), independent risk factor for plays crucial role mediating pathological effects observed. Understanding multifaceted impact heart, muscle, early detection stratification. knowledge timely implementing management strategies addressing multi-organ involvement pathogenesis.

Language: Английский

---

The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)

Cardiovascular Diabetology, Journal Year: 2025, Volume and Issue: 24(1)

Published: Feb. 7, 2025

Heart failure with preserved ejection fraction (HFpEF) is a prevalent and complex condition limited effective treatments. Endothelial dysfunction significant component of HFpEF pathophysiology, glucagon-like peptide-1 receptor (GLP-1R) agonists have shown potential benefits in improving endothelial function. This study aims to explore the relationship between mechanisms action GLP-1R agonists, highlighting their therapeutic benefits. A comprehensive review literature was conducted examine etiology HFpEF, role dysfunction, effects on function heart outcomes. The findings indicate that associated various comorbidities, such as obesity, diabetes mellitus, hypertension, which contribute dysfunction. including semaglutide liraglutide, demonstrated cardioprotective effects, vascular function, reducing inflammation, preventing atherosclerosis. Clinical trials, STEP-HFpEF trial, positive results symptoms physical restrictions patients. present promising option for by targeting other pathophysiological mechanisms. Further research needed elucidate precise through exert establish long-term safety efficacy diverse populations.

Language: Английский

---

Resistance Exercise in Treating Heart Failure with Preserved Ejection Fraction (HFpEF) and Obesity: Targeting Skeletal Muscle Abnormalities and Ectopic Adipose Depots

Physiologia, Journal Year: 2025, Volume and Issue: 5(1), P. 10 - 10

Published: Feb. 27, 2025

Heart failure is a leading cause of morbidity and mortality worldwide [...]

Language: Английский

---

Non-alcoholic fatty liver disease is associated with a worse prognosis in patients with heart failure: A pool analysis

Frontiers in Endocrinology, Journal Year: 2023, Volume and Issue: 14

Published: April 20, 2023

Background and aims Non-alcoholic fatty liver disease (NAFLD) is associated with a higher risk of heart failure (HF) than those without NAFLD. However, the prognostic impact NAFLD in HF still controversial. This meta-analysis aimed to explore association between adverse outcomes patients HF. Methods We searched multiple electronic databases (Embase, PubMed, Google Scholar) for potentially related studies up June 30, 2022. Cohort reported multivariable adjusted relative risks 95% confidence intervals (CIs) comparing were included analysis. Results A total six involving 12,374 analysis, median follow-up duration 2.5 years. The pooled analysis showed that significantly increased major composite (HR 1.61, CI 1.25-2.07), all-cause mortality 1.66, 1.39-1.98), hospitalization or re-hospitalization 1.71, 1.03-2.86). Conclusion worse prognosis Effective screening treatment strategies are needed improve

Language: Английский

---

Liraglutide With Metformin Therapy Ameliorates Hepatic Steatosis and Liver Injury in a Mouse Model of Non-alcoholic Steatohepatitis

In Vivo, Journal Year: 2023, Volume and Issue: 37(3), P. 1037 - 1046

Published: Jan. 1, 2023

Non-alcoholic fatty liver disease is a major cause of liver-related morbidity and mortality. Metformin widely used medication may have additional benefits beyond glycemic control. Liraglutide, novel treatment for diabetes obesity, also has beneficial effects on non-alcoholic steatohepatitis (NASH). liraglutide both benefited NASH treatment. However, no study reported the combination therapy with metformin NASH.We investigated in vivo methionine/choline-deficient (MCD) diet-fed C57BL/6JNarl mouse model. Serum triglyceride, alanine aminotransferase levels were documented. Histological analysis was performed according to activity grade.After metformin, body weight loss improved, liver/body ratio decreased. The metabolic injury improved. Liraglutide alleviated MCD-induced hepatic steatosis injury. revealed that reduced.Our results provide evidence anti-NASH metformin. offer potential disease-modifying intervention NASH.

Language: Английский

---

Hypoglycemic Drugs in Patients with Diabetes Mellitus and Heart Failure: A Narrative Review

Medicina, Journal Year: 2024, Volume and Issue: 60(6), P. 912 - 912

Published: May 30, 2024

Over the last few years, given increase in incidence and prevalence of both type 2 diabetes mellitus (T2DM) heart failure (HF), it became crucial to develop guidelines for optimal preventive treatment strategies individuals facing these coexisting conditions. In patients aged over 65, HF hospitalization stands out as predominant reason hospital admissions, with their prognosis being associated presence or absence T2DM. Historically, certain classes glucose-lowering drugs, such thiazolidinediones (rosiglitazone), raised concerns due an observed increased risk myocardial infarction (MI) cardiovascular (CV)-related mortality. response concerns, regulatory agencies started requiring CV outcome trials all novel antidiabetic agents [i.e., dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose cotransporter-2 (SGLT2is)] aim assess safety drugs beyond glycemic control. This narrative review aims address current knowledge about impact used T2DM on prevention, prognosis, outcome.

Language: Английский

---

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 29, 2024

Abstract There is a need to address the evidence gap regarding in‐hospital administration of sacubitril/valsartan in acute myocardial infarction patients. After searching MEDLINE, Google Scholars and Scopus, random‐effects meta‐analysis randomized controlled trials comparing angiotensin receptor‐neprilysin inhibitors (ARNis) versus standard therapy patients with reduced heart failure due was performed. The primary outcome major adverse cardiovascular events. All‐cause mortality, cardiac death, rehospitalization for failure, non‐fatal (MI), changes left ventricular ejection fraction, volumes, N terminal pro brain natriuretic peptide events were secondary endpoints. Nine studies (eight one echo‐substudy) total 6597 individuals (angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker: 3300 vs. ARNis: 3297 patients) included quantitative analysis. Median follow‐up 6 months. Patients receiving an coadministration ARNi had lower risk event [odds ratio (OR) 0.45, 95% confidence interval (CI) 0.32–0.63, P < 0.0001] rate repeat (OR 0.40, CI 0.26–0.62, 0.0001), compared regimen. Additionally, ventricle volumes significantly group [left end‐diastolic volume, mean difference (MD) 11.48 mL, 6.10–16.85, 0.0001; end‐systolic MD 7.09 2.89–11.29, = 0.0009] significant change fraction (MD 3.07, 1.61–4.53, therapy. No differences observed terms all cause peptide. Higher rates iatrogenic hypotensive 1.42, 1.26–1.60, value 0.00001). In related ARNis associated re‐hospitalization as well remodelling, but higher

Language: Английский

---

Exercise-mediated epigenetic modifications in cardiovascular diseases

Epigenomics, Journal Year: 2024, Volume and Issue: 17(3), P. 179 - 191

Published: Dec. 30, 2024

Cardiovascular diseases (CVDs) represent a prominent contributor to global morbidity and mortality rates, with projections indicating rise in this burden due population aging. While extensive research has underscored the efficacy of exercise mitigating risk CVDs, precise mechanisms, particularly within realm epigenetics, remain nascent. This article delves into cutting-edge concerning exercise-induced epigenetic alterations their impact on CVDs. Initially, we examine cardiac implications stemming from influences across varying intensities. Subsequently, our focus shifts toward delineating mechanisms governing DNA methylation, lactylation modifications, N6-methyladenosine (m6A) RNA alongside addressing associated challenges outlining prospective directions. These findings suggest that exercise-mediated modifications offer promising therapeutic potential for prevention comorbidity management However, heterogeneity tissue specificity these effects necessitate more targeted unlock full potential.

Language: Английский

---

Metabolic Dysfunction-Associated Steatotic Liver Disease and Heart Failure with Preserved Ejection Fraction: A Bidirectional Relationship with Clinical and Therapeutic Implications

Deleted Journal, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 17

Published: Sept. 18, 2024

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly prevalent and the most common cause of chronic in western world. It considered hepatic manifestation metabolic syndrome ultimately leads to cardiovascular diseases, which are leading death. Heart failure with preserved ejection fraction (HFpEF) appears be a complication MASLD and, conversely, seems exacerbate its severity. This review focuses on pathophysiological association between HFpEF, as well their clinical therapeutic implications. Summary: The connection HFpEF intricate bidirectional, involving several mechanisms, such insulin resistance, overactivation renin-angiotensin-aldosterone sympathetic nervous systems, systemic inflammation, gut dysbiosis. an independent risk factor for diastolic dysfunction increasing hospitalization death those established heart failure. Conversely, exacerbates severity MASLD. Screening fibrosis should conducted stable euvolemic patients utilizing ultrasonography Fibrosis-4 index. performed measurement natriuretic peptides; however, these may have lower sensitivity echocardiography needed. Therapeutic strategies both limited, but certain interventions studied also benefit system. Lifestyle interventions, adherence Mediterranean diet weight loss, proven beneficial diseases. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) incretin mimetics show promise treating conditions synergistic effects. Key Messages: increases incident worsens prognosis HFpEF. Given high prevalence screening crucial. begin peptides when there suspicion. SGLT2i glucagon-like peptide-1 receptor agonists offer benefits

Language: Английский

---